BACKGROUND: Unloading a failing heart with a left ventricular assist device (LVAD) can improve ejection fraction (EF) and LV size; however, recovery with LVAD explantation is rare. We hypothesized that evaluation of myocyte contractility and biochemistry at the sarcomere level before and after LVAD may explain organ-level changes. METHODS AND RESULTS: Paired LV tissue samples were frozen from 8 patients with nonischemic cardiomyopathy at LVAD implantation (before LVAD) and before cardiac transplantation (after LVAD). These were compared with 8 nonfailing hearts. Isolated skinned myocytes were purified and attached to a force transducer, and dimensions, maximum calcium-saturated force, calcium sensitivity, and myofilament cooperativity were assessed. Relative isoform abundance and phosphorylation levels of sarcomeric contractile proteins were measured. With LVAD support, the unloaded EF improved (10.0±1.0% to 25.6±11.0%, P=0.007), LV size decreased (LV internal dimension at end diastole, 7.6±1.2 to 4.9±1.4 cm; P<0.001), and myocyte dimensions decreased (cross-sectional area, 1247±346 to 638±254 μm(2); P=0.001). Maximum calcium-saturated force improved after LVAD (3.6±0.9 to 7.3±1.8 mN/mm(2), P<0.001) implantation but was still lower than in nonfailing hearts (7.3±1.8 versus 17.6±1.8 mN/mm(2), P<0.001). An increase in troponin I (TnI) phosphorylation after LVAD implantation was noted, but protein kinase C phosphorylation of TnI decreased. Biochemical changes of other sarcomeric proteins were not observed after LVAD. CONCLUSIONS: There is significant improvement in LV and myocyte size with LVAD, but there is only partial recovery of EF and myocyte contractility. LVAD support was associated only with biochemical changes in TnI, suggesting that alternate mechanisms might contribute to contractile changes after LVAD and that additional interventions may be needed to alter biochemical remodeling of the sarcomere to further enhance myofilament and organ-level recovery.
BACKGROUND: Unloading a failing heart with a left ventricular assist device (LVAD) can improve ejection fraction (EF) and LV size; however, recovery with LVAD explantation is rare. We hypothesized that evaluation of myocyte contractility and biochemistry at the sarcomere level before and after LVAD may explain organ-level changes. METHODS AND RESULTS: Paired LV tissue samples were frozen from 8 patients with nonischemic cardiomyopathy at LVAD implantation (before LVAD) and before cardiac transplantation (after LVAD). These were compared with 8 nonfailing hearts. Isolated skinned myocytes were purified and attached to a force transducer, and dimensions, maximum calcium-saturated force, calcium sensitivity, and myofilament cooperativity were assessed. Relative isoform abundance and phosphorylation levels of sarcomeric contractile proteins were measured. With LVAD support, the unloaded EF improved (10.0±1.0% to 25.6±11.0%, P=0.007), LV size decreased (LV internal dimension at end diastole, 7.6±1.2 to 4.9±1.4 cm; P<0.001), and myocyte dimensions decreased (cross-sectional area, 1247±346 to 638±254 μm(2); P=0.001). Maximum calcium-saturated force improved after LVAD (3.6±0.9 to 7.3±1.8 mN/mm(2), P<0.001) implantation but was still lower than in nonfailing hearts (7.3±1.8 versus 17.6±1.8 mN/mm(2), P<0.001). An increase in troponin I (TnI) phosphorylation after LVAD implantation was noted, but protein kinase C phosphorylation of TnI decreased. Biochemical changes of other sarcomeric proteins were not observed after LVAD. CONCLUSIONS: There is significant improvement in LV and myocyte size with LVAD, but there is only partial recovery of EF and myocyte contractility. LVAD support was associated only with biochemical changes in TnI, suggesting that alternate mechanisms might contribute to contractile changes after LVAD and that additional interventions may be needed to alter biochemical remodeling of the sarcomere to further enhance myofilament and organ-level recovery.
Authors: Teruo Noguchi; Mark Hünlich; Phillip C Camp; Kelly J Begin; Mohamed El-Zaru; Richard Patten; Bruce J Leavitt; Frank P Ittleman; Norman R Alpert; Martin M LeWinter; Peter VanBuren Journal: Circulation Date: 2004-08-09 Impact factor: 29.690
Authors: Lori A Walker; Allen M Medway; John S Walker; Joseph C Cleveland; Peter M Buttrick Journal: J Muscle Res Cell Motil Date: 2010-12-24 Impact factor: 2.698
Authors: Stefan Klotz; Alessandro Barbone; Steven Reiken; Jeffrey W Holmes; Yoshifumi Naka; Mehmet C Oz; Andrew R Marks; Daniel Burkhoff Journal: J Am Coll Cardiol Date: 2005-03-01 Impact factor: 24.094
Authors: G Torre-Amione; S J Stetson; K A Youker; J B Durand; B Radovancevic; R M Delgado; O H Frazier; M L Entman; G P Noon Journal: Circulation Date: 1999-09-14 Impact factor: 29.690
Authors: Emma J Birks; Patrick D Tansley; James Hardy; Robert S George; Christopher T Bowles; Margaret Burke; Nicholas R Banner; Asghar Khaghani; Magdi H Yacoub Journal: N Engl J Med Date: 2006-11-02 Impact factor: 91.245
Authors: Nazha Hamdani; Walter J Paulus; Loek van Heerebeek; Attila Borbély; Nicky M Boontje; Marian J Zuidwijk; Jean G F Bronzwaer; Warner S Simonides; Hans W M Niessen; Ger J M Stienen; Jolanda van der Velden Journal: Eur Heart J Date: 2009-05-31 Impact factor: 29.983
Authors: Stavros G Drakos; Abdallah G Kfoury; Josef Stehlik; Craig H Selzman; Bruce B Reid; John V Terrovitis; John N Nanas; Dean Y Li Journal: Circulation Date: 2012-07-10 Impact factor: 29.690
Authors: Mosi K Bennett; Wendy E Sweet; Sara Baicker-McKee; Elizabeth Looney; Kristen Karohl; Maria Mountis; W H Wilson Tang; Randall C Starling; Christine S Moravec Journal: Circ Heart Fail Date: 2014-05-19 Impact factor: 8.790
Authors: Premi Haynes; Kristofer E Nava; Benjamin A Lawson; Charles S Chung; Mihail I Mitov; Stuart G Campbell; Arnold J Stromberg; Sakthivel Sadayappan; Mark R Bonnell; Charles W Hoopes; Kenneth S Campbell Journal: J Mol Cell Cardiol Date: 2014-02-20 Impact factor: 5.000
Authors: Jonathan A Kirk; Ronald J Holewinski; Viola Kooij; Giulio Agnetti; Richard S Tunin; Namthip Witayavanitkul; Pieter P de Tombe; Wei Dong Gao; Jennifer Van Eyk; David A Kass Journal: J Clin Invest Date: 2014-01 Impact factor: 14.808
Authors: Matthew S Stratton; Charles Y Lin; Priti Anand; Philip D Tatman; Bradley S Ferguson; Sean T Wickers; Amrut V Ambardekar; Carmen C Sucharov; James E Bradner; Saptarsi M Haldar; Timothy A McKinsey Journal: Cell Rep Date: 2016-07-14 Impact factor: 9.423
Authors: Jonathan A Kirk; Khalid Chakir; Kyoung Hwan Lee; Edward Karst; Ronald J Holewinski; Gianluigi Pironti; Richard S Tunin; Iraklis Pozios; Theodore P Abraham; Pieter de Tombe; Howard A Rockman; Jennifer E Van Eyk; Roger Craig; Taraneh G Farazi; David A Kass Journal: Sci Transl Med Date: 2015-12-23 Impact factor: 17.956